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Abstract
Introduction To review the pharmacology, pharmacoki-
netics, eYcacy, and safety of daptomycin, a novel antibiotic
for the treatment of bone and joint infections, a literature
search of relevant articles was conducted.
Materials and methods A PubMed/MEDLINE search
(1990–April 2008) to identify relevant English-language
literature was conducted. Search terms included bone and
joint infection, osteomyelitis, daptomycin, and methicillin-
resistant  Staphylococcus aureus (MRSA). Additional
articles were identiWed by reviewing the bibliographies of
articles cited. Programs and abstracts from infectious disease
meetings were searched, and prescribing information of
antibiotics indicated for bone and joint infections consulted.
All articles identiWed from data sources published in
English were evaluated.
Results Caused primarily by Gram-positive pathogens
such as S. aureus and, to a lesser extent, Enterococcus
faecalis, bone and joint infections are diYcult to treat success-
fully. Surgical intervention and prolonged courses of antibi-
otics are frequently required, and failure of Wrst-line
antibiotic therapy is common. The emergence of S. aureus
strains with reduced susceptibility to vancomycin, the long-
standing gold standard for bone and joint infections, has
complicated the clinical scenario. Few randomized trials
comparing the eYcacy of diVerent antibiotics for bone and
joint infections exist. Daptomycin, a novel intravenous lip-
opeptide antibiotic, has shown potent in vitro activity
against a broad spectrum of Gram-positive bacteria, includ-
ing many resistant pathogens commonly associated with
bone and joint infections such as MRSA and vancomycin-
resistant E. faecalis. Early clinical investigation of dapto-
mycin in bone and joint infections unresponsive to antibiot-
ics, such as vancomycin, has found a cure rate of
approximately 80%, with a low incidence of adverse events
and drug resistance.
Conclusion Further studies are warranted to determine if
limited clinical evidence, described in individual case
reports and a daptomycin-speciWc retrospective registry,
suggests daptomycin is a promising option for patients with
bone and joint infections such as MRSA osteomyelitis.
Keywords Bone · Daptomycin · Infection · 
Osteomyelitis · MRSA · VRE
Introduction
The treatment of bone and joint infections such as osteomy-
elitis, septic arthritis, and prosthetic joint infections can be
diYcult, requiring prolonged administration of antibiotics
and extensive surgical procedures [1]. Most bone and joint
infections are caused by Gram-positive cocci including
Staphylococcus spp. and enterococci [1], increasingly resis-
tant to commonly used antibiotics such as methicillin and
other -lactam agents [2, 3]. Vancomycin is often used to
treat bone and joint infections caused by methicillin-resis-
tant  Staphylococcus  aureus (MRSA), an organism seen
with increasing frequency [4]. MRSA has recently emerged
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as an important cause of community-acquired infection in
many parts of the United States [5], and recent surveys of
S. aureus isolates report MRSA rates as high as 74% [6, 7].
Although vancomycin remains a Wrst-line treatment for
many bone and joint infections caused by typical organ-
isms, its eYcacy against MRSA infections in other settings
is declining ominously [8]. This reduced susceptibility of
S. aureus to vancomycin [3,  9] may be partially due to
S. aureus-produced bioWlms, which may facilitate resistance
by promoting horizontal gene transfer [10–12]. The ability
of pathogens to escape lysis and killing by vancomycin,
termed “tolerance,” represents an additional risk. Both
genetic and physiologic factors can selectively suppress
susceptibility to the killing action of antibiotics without
a change in the minimum inhibitory concentration (MIC),
i.e., can make bacteria antibiotic-tolerant and diYcult to
detect using standard susceptibility testing methods
[13, 14].
Selection of antimicrobial therapy for bone 
and joint infections
Most cases of osteomyelitis require antimicrobial therapy,
adequate drainage, thorough debridement, obliteration of
dead space, and wound protection. Patients are initially
treated empirically with broad-spectrum antimicrobials,
changed to targeted antimicrobial therapy based on bone
culture results of samples taken at debridement surgery or
from deep bone biopsies. Septic arthritis, a medical emer-
gency, requires prompt recognition and aggressive treat-
ment for a good prognosis [15]. Delays in surgical
drainage and antibiotic therapy may lead to progressive
synovitis and irreversible destruction of cartilage and bone
[16,  17]. Empirical antibiotic therapy directed against
staphylococci, the most common causative organisms of
septic arthritis in adults, should be given while awaiting
culture results [15, 18]. If the Gram stain is negative in
acute septic arthritis, empirical therapy should include an
antimicrobial having activity against S. aureus and strepto-
cocci [15, 19]. Antibiotic therapy of prosthetic joint infec-
tions is based on a deWnitive microbiologic diagnosis,
usually after the surgical removal of all bioprosthetic com-
ponents [15].
Despite these general guidelines, high-quality evidence
of the relative eVectiveness of various regimens of antibi-
otic therapy, and their optimal duration, is scant [20].
A 2001 meta-analysis concluded that little high-quality evi-
dence-based therapy for osteomyelitis and septic arthritis
exists [21]. Increasing resistance to antibiotics has
prompted the development of new drugs to treat Gram-
positive infections, which may also be used in the treatment
of bone and joint infections.
Current treatment options for S. aureus bone and joint 
infections
Staphylococcus aureus is the most common organism
implicated in osteomyelitis and septic arthritis [1,  15].
Although the term MRSA denotes resistance to methicillin,
it is synonymous with multidrug-resistant S. aureus,
because many nosocomial MRSA strains are resistant to
many other commonly used antibiotics. Approximately
20% of S. aureus isolates in Europe are reported as methi-
cillin-resistant; the prevalence ranges from 33 to 55% in US
hospitals. Since 1996, seven vancomycin-intermediate
S. aureus (VISA) strains (i.e., vancomycin MIC = 8–16 mg/L)
have been identiWed in Europe, Asia, and the United States,
and VISA strains (vancomycin MIC ¸ 32 mg/L) were
also reported in the United States between 2002 and 2005
[22].
Vancomycin was the last available drug to which
S. aureus had remained uniformly sensitive, until recent
reports of low-level glycopeptide resistance and the transfer
of high-level vancomycin resistance from Enterococcus to
S. aureus [23, 24]. A limited number of broad-spectrum
antimicrobials are available to combat multidrug-resistant
Gram-positive organisms.
Vancomycin
In 1997, the Wrst clinical isolate of S. aureus having inter-
mediate resistance to vancomycin was reported from Japan
[25]. Since then, many S. aureus isolates with reduced
susceptibility to glycopeptides have been reported from
various locales [23, 26]. The Wrst report of vancomycin-
resistant S. aureus in the United States occurred in 2002.
The patient had been treated with multiple antibiotics,
including vancomycin. MRSA bacteremia later developed,
and the patient was treated with vancomycin and rifampin.
The Centers for Disease Control and Prevention conWrmed
that the S. aureus isolated was resistant to oxacillin, vanco-
mycin, and teicoplanin [3].
Vancomycin itself has poor bone penetration and in
some animal studies has shown an inability to sterilize bone
[27, 28]. When bone and joint pathogens are susceptible,
vancomycin concentrations in serum must be monitored,
and vancomycin-associated adverse events (e.g., marrow
suppression, ototoxicity, nephrotoxicity, and rash) may dis-
courage its use [29]. Adverse eVects, increasing MICs, and
the increased prevalence of vancomycin-resistant entero-
cocci (VRE), VISA, and vancomycin-resistant S. aureus
(VRSA) are already limiting the use of vancomycin in the
treatment of bone and joint infections [23, 26, 30, 31]. Van-
comycin-susceptible clinical MRSA isolates demonstrate
considerable heterogeneity in vitro with respect to vanco-
mycin MIC and vancomycin killing, aVecting the clinicalArch Orthop Trauma Surg (2009) 129:1495–1504 1497
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eYcacy of the drug. A signiWcant risk for vancomycin treat-
ment failure in MRSA bacteremia has been demonstrated,
with increasing vancomycin MICs still well within the sus-
ceptible range [32]. An increased risk of recurrence seen
with vancomycin treatment of S. aureus osteomyelitis [33]
further diminishes the clinical utility of this agent for the
treatment of bone and joint infections.
Quinupristin/dalfopristin
Quinupristin/dalfopristin (Q–D), the Wrst parenteral strep-
togramin, achieves a response in approximately two-thirds
of patients with MRSA infections. This combination prod-
uct also has eYcacy in patients with Gram-positive compli-
cated skin and skin structure infections (cSSIs) and
nosocomial pneumonia [34, 35]. Rifampin plus either Q–D
or vancomycin has been found signiWcantly more eVective
than monotherapy in a preclinical trial of MRSA knee
infection [36].
An evaluation of Q-D for the treatment of a variety of
MRSA infections (44% bone and joint infections) in
patients either intolerant of or failing prior therapy resulted
in an overall success rate of 71.1% in the all-treated popula-
tion (n = 90) and 66.7% in patients who were both clini-
cally and bacteriologically evaluable (n = 27). The most
common non-venous adverse events were arthralgias
(10.8%), myalgias (8.6%), and nausea (8.6%) [37]. Q–D is
not indicated for bone and joint infections, and little clinical
data exist for the drug’s use in that setting [34].
Linezolid
Linezolid is an oxazolidinone, a new class of antibacterial
agents particularly eVective against Gram-positive infec-
tions, including methicillin- and vancomycin-resistant
strains [38]. It is available in oral and intravenous (IV) for-
mulations and has been approved by the Food and Drug
Administration for the treatment of numerous infections,
including cSSIs or uncomplicated SSIs, without concomi-
tant osteomyelitis, caused by S. aureus [39]. However, data
on the eVectiveness and tolerability of linezolid as pro-
longed therapy for bone and joint infections are lacking,
and linezolid is not indicated for their treatment. No large,
randomized trials have been published on the use of linezo-
lid for orthopedic infections such as osteomyelitis and
septic arthritis. Nevertheless, a recent retrospective study of
linezolid for chronic osteomyelitis found that when used as
monotherapy, or in combination with other antimicrobials
and/or surgery, linezolid was associated with a cure rate of
85% at 12 weeks after the end of treatment and 78.8% at
follow-up. Adverse events, including anemia and periphe-
ral neuropathy, were reported in 51.5% of subjects, and
34.8% of subjects discontinued the study because of
adverse events [40]. Peripheral and optic neuropathy have
been reported in patients treated with linezolid, primarily in
patients treated for longer than the maximum recommended
duration of 28 days [39]. Early identiWcation of linezolid-
induced peripheral neuropathy is a particular concern,
because this may be irreversible [41]. Resistance to linezo-
lid has been reported among strains of both MRSA and
Enterococcus faecium [37, 42, 43].
Tigecycline
Tigecycline, the Wrst glycylcycline approved in the United
States, is indicated for cSSIs and complicated intra-abdom-
inal infections (cIAIs), not for bone and joint infections.
Tigecycline has activity against both methicillin-suscepti-
ble S. aureus (MSSA) and MRSA. In four phase III trials in
patients with cSSIs and cIAIs, tigecycline was noninferior
to its comparators (vancomycin + aztreonam in two studies
and imipenem/cilastatin in two studies), with clinical cure
rates among clinically evaluable patients of >80%
(P < 0.001 for noninferiority). Although there have been no
human trials involving osteomyelitis, animal studies sug-
gest tigecycline may have a role in treating bone infection.
After 28 days of treatment of experimentally induced osteo-
myelitis, rabbits receiving tigecycline/oral rifampicin
showed a 100% infection clearance [44]. Frequently
reported adverse events include nausea and vomiting, diar-
rhea, local IV-site reaction, infection, and fever [45, 46].
Resistance to tigecycline has been reported among both
Gram-positive and Gram-negative strains.
Daptomycin
This novel cyclic lipopeptide is bactericidal against Gram-
positive bacteria, including MRSA and VRE. Daptomycin
kills Gram-positive bacteria by disruption of multiple bac-
terial plasma membrane functions, without penetrating the
cytoplasm [47]. Insertion of the lipophilic daptomycin tail
into the bacterial cell membrane causes rapid membrane
depolarization and a potassium ion eZux. Arrest of DNA,
RNA, toxin production, and protein synthesis follows,
resulting in bacterial cell death without lysis of the cell wall
(Fig. 1) [48–50].
Microbiology
The in vitro potency of daptomycin has been demonstrated
against a wide range of aerobic and anaerobic Gram-
positive bacteria, including MRSA, glycopeptide-interme-
diate  S. aureus, methicillin-resistant coagulase-negative
staphylococci, and VRE [47]. The in vitro activity of dapto-
mycin against three VISA isolates was compared with that
of vancomycin, linezolid, and Q–D. Overall, daptomycin1498 Arch Orthop Trauma Surg (2009) 129:1495–1504
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was more active against all organisms tested, except E. fae-
cium and VISA, against which its activity was similar to
that of Q–D. In time-kill studies with MRSA, MRSE, VRE,
and VISA, daptomycin demonstrated greater bactericidal
activity than all others tested, killing ¸3l o g  C F U / m L
within 8 h [51]. Daptomycin is also eVective against a vari-
ety of streptococci, such as -hemolytic streptococci and
other  Streptococcus spp. [52]. Susceptibility criteria are
shown in Table 1. Synergy with daptomycin has been
described in vitro with aminoglycosides, i.e., gentamicin,
oxacillin, other -lactams, and rifampicin [47, 53, 54]. Dap-
tomycin exhibits a dose-dependent post-antibiotic eVect
lasting from 1 to 6 h against E. faecalis and S. aureus after
exposure to concentrations ranging from 0.25 to 16 mg/L
(i.e., between one- and eightfold the MIC) [55].
Pharmacology
With an 8-h half-life, once-daily dosing results in linear
pharmacokinetics at doses up to 12 mg/kg, with minimal
drug accumulation (Table 2) [47]. Daptomycin distributes
primarily in the plasma, with penetration to vascularized
tissues. The drug is highly protein-bound (92%); excretion
occurs primarily via the kidneys. Approximately 80% of
the total dose, of which two-thirds is intact drug, is recovered
in the urine [47, 56]. In patients with severe renal impair-
ment (creatinine clearance < 30 mL/min), the dosing interval
is increased from once daily to every 48 h. Daptomycin’s
unique mechanism of action and its lack of metabolization
by cytochrome P450 or other hepatic enzymes results in an
absence of drug–drug interactions. Against 70 clinical iso-
lates, interactions between daptomycin and 25 antimicrobi-
als were additive or indiVerent; antagonism was not
observed. Synergistic interactions were observed between
daptomycin and gentamicin against staphylococci and
enterococci, including strains resistant to methicillin and
vancomycin; in vitro synergistic interactions of daptomycin
and rifampin have been shown against methicillin- and
vancomycin-resistant staphylococci and enterococci
[47, 56].
Skeletal muscle was the most sensitive tissue to the
adverse eVects of daptomycin in animal studies. Mild
myopathy was easily predicted and monitored by measur-
ing serum creatine phosphokinase concentrations; the eVect
was reversible upon the cessation of therapy [47, 56]. Dog
studies demonstrated that adverse eVects increased with
fractionated compared with once-daily administration of
the same total daily dose. Thus, once-daily dosing may
increase the therapeutic-toxicity ratio by increasing eYcacy
and decreasing adverse eVects [57].
Preclinical eYcacy of daptomycin in bone 
and joint infection models
The eYcacy of daptomycin against a range of infections
has been demonstrated in animal studies. Using a variety of
antibiotic-resistant and antibiotic-sensitive Gram-positive
bacteria, daptomycin eradicated infections in the blood,
muscle, kidney, heart, and bone tissues of animals [57–64].
In a rat model of chronic MSSA osteomyelitis, daptomycin
10 mg/kg subcutaneously every 12 h resulted in bacterial
numbers similar to those of untreated animals, a Wnding
Fig. 1 Mechanism of action of daptomycin [48]. Reprinted with per-
mission. Step 1 calcium-dependent binding and insertion of the lipo-
philic tail into Gram-positive cytoplasmic membrane. Step 2
oligomerization and channel formation occur. Step 3 ion leakage and
collapse of organism lead to cell death
Step 3 Step 2
K+
K+
K+
Step 1
Ca2+
Ca2+ Ca2+
Ca2+
Daptomycin
Ca2+
Table 1 Daptomycin susceptibility criteria [47]
I intermediate, R resistant, S susceptible
a The mean inhibitory concentration (MIC) interpretive criteria for S. aureus and E. faecalis are applicable only to tests performed by broth dilution
using Mueller–Hinton broth adjusted to a calcium content of 50 mg/L; the MIC interpretive criteria for Streptococcus spp. other than S. pneumo-
niae are applicable only to tests performed by broth dilution using Mueller–Hinton broth adjusted to a calcium content of 50 mg/L, supplemented
with 2–5% lysed horse blood, inoculated with a direct colony suspension and incubated in ambient air at 35°C for 20–24 h
b The current absence of data on daptomycin-resistant isolates precludes deWning any categories other than “susceptible.” Isolates yielding test
results suggestive of a “non-susceptible” category should be retested, and if the result is conWrmed, the isolate should be submitted to a reference
laboratory for further testing
Pathogen Broth dilution MICa (g/mL)
SI R
Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) ·1 bb
Streptococcus pyogenes, S. agalactiae, and S. dysgalactiae sub-spp. equisimilis ·1 bb
Enterococcus faecalis (vancomycin-susceptible only) ·4 bbArch Orthop Trauma Surg (2009) 129:1495–1504 1499
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possibly related to underdosing [65]. Examination of
several doses of daptomycin in an experimental murine
S. aureus thigh infection model demonstrated concentra-
tion-dependent bactericidal activity. A mean peak/MIC
ratio of 255 or a mean 24-h area under the concentration–
time curve (AUC)/MIC ratio of 1,061 was needed to eVect
a 2 log10 reduction in vivo [66].
Daptomycin reduced bacterial cultures of bone infected
with S. aureus in an experimental osteomyelitis rabbit model
[63]. Daptomycin was as eVective as vancomycin at compa-
rable peak plasma levels of approximately 33 g/mL for the
two drugs [63]. High-dose daptomycin was compared with
standard regimens of oxacillin and vancomycin in a diYcult-
to-treat rat tissue cage model of chronic S. aureus foreign
body infection, so called as perforated TeXon cylinders are
implanted subcutaneously in rats, and infected, in this case
with MSSA strain I20, a clinical isolate from catheter-related
sepsis. In vitro elimination of strain I20 was more rapid with
8 mg/L of daptomycin than with oxacillin or vancomycin at
the same dose. After 7 days of therapy, the mean (§SEM)
reduction in viable counts of MSSA I20 was 2.62
(§0.30) log10 CFU/mL in cages (n = 18) of daptomycin-
treated rats, exceeding by more than twofold (P <0 . 0 1 )  t h e
viable count reductions in cages of oxacillin-treated and van-
comycin-treated rats, respectively [67]. A comparative
experiment of daptomycin and vancomycin in a rabbit model
of MRSA osteomyelitis found that ten rabbits given dapto-
mycin 25 mg/kg per day showed a 90% infection clearance,
nine rabbits treated with daptomycin 15 mg/kg per day
showed a 66.67% clearance, and eight rabbits treated with
vancomycin showed a 33.3% clearance. Untreated controls
(n = 15) demonstrated only a 13.3% clearance [68].
Daptomycin in bone and joint infections
Daptomycin was initially approved in 2003 for the treat-
ment of cSSIs caused by S. aureus (including methicillin-
resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae
sub-spp. equisimilis, and E. faecalis (vancomycin-suscepti-
ble strains only) at a dose of 4 mg/kg per day administered
IV. More than 90% of vancomycin-resistant E. faecalis iso-
lates have demonstrated an in vitro MIC · the susceptible
breakpoint for daptomycin, but the eYcacy of daptomycin
in treating clinical infections caused by these microorgan-
isms has not been established in clinical trials [47]. In 2006,
daptomycin was approved as a once-daily therapy (6 mg/
kg) for the treatment of S. aureus bloodstream infections
(bacteremia), including right-sided endocarditis caused by
MSSA and MRSA [47].
The use of daptomycin has been investigated in bone and
joint infections. Case records of a prospective, randomized
trial of daptomycin alone versus gentamicin plus either
semisynthetic penicillin or vancomycin for S. aureus bac-
teremia and endocarditis [8] were retrospectively assessed
to identify patients in the trial with concomitant compli-
cated bone and joint infections (i.e., osteomyelitis or septic
arthritis). Bone and joint infections were found in 21 of 120
patients treated with daptomycin (17.5%) and 11 of 115
control patients (9.6%). Treatment success was achieved in
16 patients treated with daptomycin by the end of therapy
(76.2%) and was maintained in 14 patients (66.7%)
6 weeks after the end of therapy. Seven of 11 control
patients achieved a successful outcome by the end of ther-
apy (63.6%), with 6 patients (54.6%) maintaining success
6 weeks later [69].
A second retrospective chart review of patients with
osteomyelitis treated with daptomycin was conducted at six
sites in the United States. Anatomic sites of infection
included the lower extremity (45%), upper extremity
(24%), vertebrae (21%), and sternum/chest wall (10%);
41% of patients had prosthetic material present. The most
common pathogen isolated was MRSA (64%). Fifty-two
percent of patients received an antibiotic within 4 weeks of
daptomycin treatment (vancomycin in 67% of cases).
Forty-Wve percent of patients started daptomycin because
previous therapy had failed. The median daptomycin dos-
age was 4.2 mg/kg (range 3.5–7.1 mg/kg), and the median
Table 2 Pharmacokinetic parameters of daptomycin at steady-state in healthy subjects [47]
AUC0–24, area under the concentration-time curve from 0 to 24 h; t1/2, terminal elimination half-life; Vss, volume of distribution at steady-state;
CLT, plasma clearance; Cmax, maximum plasma concentration
a Doses of daptomycin > 6 mg/kg have not been approved
Dose (mg/kg)a Pharmacokinetic parameters
AUC0–24 (g h/mL) t1/2 (h) Vss (L/kg) CLT (mL/h per kg) Cmax (g/mL)
4 (n = 6) 494 (75) 8.1 (1.0) 0.096 (0.009) 8.3 (1.3) 57.8 (3.0)
6 (n = 6) 632 (78) 7.9 (1.0) 0.101 (0.007) 9.1 (1.5) 93.9 (6.0)
8 (n = 6) 858 (213) 8.3 (2.2) 0.101 (0.013) 9.0 (3.0) 123.3 (16.0)
10 (n = 9) 1,039 (178) 7.9 (0.6) 0.098 (0.017) 8.8 (2.2) 141.1 (24.0)
12 (n = 9) 1,277 (253) 7.7 (1.1) 0.097 (0.018) 9.0 (2.8) 183.7 (25.0)1500 Arch Orthop Trauma Surg (2009) 129:1495–1504
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duration of therapy was 42 days (range 18–63 days). Forty-
eight percent of patients received an antibiotic along with
daptomycin, most commonly rifampin. Outcomes at end of
therapy were cure (16/29, 55%), improved (10/29, 34%),
and failure (3/29, 10%). Outcomes at follow-up were cure
(19/29, 65%), improved (1/29, 3%), and failure (9/29,
31%). Clinical success (i.e., cure plus improved) was
achieved with daptomycin in 90% of patients with osteo-
myelitis by the end of therapy, despite the large percentage
who had failed treatment with prior antibiotics. Clinical
success was maintained in 69% of patients at ¸6m o n t h s ’
follow-up. During the study period, there were six adverse
events reported in six patients, all mild to moderate in
severity [70].
Three case series on the use of daptomycin in bone and
joint infections included 22 male and 31 female patients
with a mean age of 65.8 years [33, 41, 71, 72]. Osteomyeli-
tis was diagnosed in 43% of patients; other infections
included total joint arthroplasty, laminectomy site infec-
tion, knee abscess, and bacteremia associated with septic
arthritis. MRSA was isolated as the pathogen in 74% of
patients, and more than one pathogen was isolated in 11%
of cases. Daptomycin was given at a dosage of 4–6 mg/kg
per day for a mean duration of 37.4 days. Patients were pre-
viously treated with antibiotics such as vancomycin, rifam-
picin, ciproXoxacin, linezolid, and Q–D. Cure of infection
was achieved with daptomycin in 81% of cases, with a cure
rate of 100% among patients with osteomyelitis and 60% of
total joint arthroplasty infection cases. Development of
non-susceptibility to daptomycin occurred in one case of
MRSA infection of an epidural abscess [33]. A summary of
ten patients from one case series who were treated with
daptomycin for various bone and joint infections is shown
in Table 3. Whether the eVectiveness of treatment of bone
and joint infection in each of these three case series can be
solely attributed to daptomycin is uncertain, since other
antibiotics were co-administered in most of the cases [41];
however, as previously stated, most of these patients had
been treated with other antibiotics that did not result in a
positive outcome, necessitating the change to daptomycin.
The outcomes of 25 patients with foot or ankle osteomy-
elitis who were treated with daptomycin at a median dose
of 6 mg/kg (range 4–6.2 mg/kg) for a median duration of
38 days (range 6–59 days) were recently reported [73].
Twenty-three patients received daptomycin as secondary or
tertiary therapy, primarily because they had not responded
to prior antibiotic treatment (n = 15). Concomitant antibiot-
ics were given to 11 patients, mostly for Gram-negative
and/or anaerobic coverage. MRSA was the most common
pathogen overall (15 of 25 patients). At the end of therapy,
16 patients’ symptoms had resolved, eight patients
improved, and one patient did not respond to therapy. At a
median follow-up of 9 weeks, 19 patients’ symptoms
resolved, three patients improved, and three patients did not
respond to therapy. Additional antibiotics were given to
52% of patients for a minimum of 8 days (median 30 days,
range 8–232 days). Four patients with an implant (all
removed) were successfully treated. Daptomycin appeared
to be eVective for previously treated foot and ankle osteo-
myelitis caused by Gram-positive bacteria in this trial, war-
ranting additional controlled clinical studies of daptomycin
as an alternative agent for patients with bone and joint
Table 3 Case summary of patients with bone and joint infections treated with daptomycin [33]
Reprinted with permission
Osteo osteomyelitis, bact bacteremia, MRSA methicillin-resistant Staphylococcus aureus, Entero Enterococcus faecalis, Strep presumed strepto-
coccus infection (no cultures available), VAN vancomycin, GEN gentamicin, LIN linezolid, QUI quinupristin/dalfopristin, MIN/RIF minocycline/
rifampin, CEF cefepime, DAP daptomycin
a Resolution of signs and symptoms associated with the infection and discharge from the hospital
b Patient was switched to ampicillin once the pathogen was identiWed and was successfully treated
Patient number Age/gender Diagnosis Pathogen Prior antibiotic DAP duration (days) Resolutiona
Rush Presbyterian St. Luke’s Medical Center
1 47/F Osteo MRSA VAN 8 Yes
2 41/M Septic joint, bact MRSA None 44 Yes
3 87/F Septic arthritis, bact MRSA VAN, GEN 41 Relapse
4 67/F Septic joint Entero VAN 4 Yes (w/amp)b
Fountain Valley Regional Hospital
5 58/F Septic arthritis, osteo, bact MRSA VAN, LIN, QUI 42 Yes
6 57/F Osteo, wound infection MRSA VAN 35 Yes
7 83/F Osteo MRSA VAN, QUI, LIN, MIN/RIF 28 Yes
8 72/M Osteo MRSA VAN 21 Yes
9 67/F Osteo, septic arthritis MRSA VAN, QUI, CEF, LIN 28 Yes
10 39/F Osteo Strep CEF 42 YesArch Orthop Trauma Surg (2009) 129:1495–1504 1501
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infections who are intolerant to other antibiotics or fail to
improve. In a recent case report, continual daptomycin use
for 18 months in a patient with MRSA osteomyelitis is
noteworthy because of the extended duration of daptomy-
cin use without signiWcant toxicity and because of ultimate
eYcacy in treating the infection [74]. To date, no random-
ized, controlled trials comparing the eVectiveness and
safety of daptomycin with other antibiotics used to treat
bone and joint infections have been completed [41].
The Cubicin Outcomes Registry and Experience
(CORE) is a multicenter retrospective observational data-
base containing information about patients treated with
daptomycin in clinical practice. The characteristics and out-
comes of patients with osteomyelitis who were treated with
daptomycin were retrospectively evaluated from the CORE
2004 database [75]. Of the 67 patients with osteomyelitis
who were clinically evaluable at the end of daptomycin
therapy, 42 (63%) were cured, 13 (19%) were improved,
7 (10%) had failure, and 5 (7%) were nonevaluable. In
about one half of the cases (48%), daptomycin was given
concurrently with other antimicrobial agents; MRSA com-
prised 45% of the pathogens. Success occurred at a 94%
rate when daptomycin was used alone, with no antimicro-
bial agents following it. These results indicate that dapto-
mycin can be eVectively used in clinical practice to treat
osteomyelitis caused by a Gram-positive organism, includ-
ing MRSA [75].
Antibiotic-loaded polymethlymethacrylate bone cement
Polymethlymethacrylate (PMMA) bone–cement spacers
have been used in the revision of infected prosthetic joints
and in the placement of orthopedic implants in patients at
high risk for infection. The ability to deliver high local con-
centrations of antimicrobial agents with PMMA has made it
a standard of care for patients with chronic infection at the
site of a total joint replacement. The most commonly used
antibiotics include tobramycin, gentamicin, vancomycin,
and cephalosporins [76, 77].
A Mayo Clinic study recently evaluated the elution of
daptomycin from PMMA in a continuous Xow chamber
designed to simulate in vivo conditions. Three-millimeter
beads containing 2.5, 7.5, and 15.0% daptomycin (weight
daptomycin per weight PMMA) were individually placed
in a chamber with 1 mL Krebs Ringer buVer  Xowing at
1 mL/h. The majority of daptomycin was released in the
Wrst 24 h. When treating osteomyelitis, achieving the high-
est local concentration of antimicrobial is important. In this
study, daptomycin eluted from 3-mm PMMA beads in a
continuous Xow chamber more completely than did vanco-
mycin when tested at the same laboratory [78]. By doubling
the amount of daptomycin in PMMA, local peak concentra-
tions of drug were signiWcantly increased [77]. In a recent
study in which daptomycin was mixed with calcium sulfate
hemihydrate to form a hardened pellet, daptomycin eluted
from calcium sulfate for up to 28 days retained the ability
to inhibit growth of S. aureus and S. epidermidis [79].
Resistance to daptomycin
As with all antibiotics, orthopedic cases of resistance to
daptomycin have been reported, including patients with
vertebral or sternal osteomyelitis, diskitis, and septic arthri-
tis [80–82], all positive for MRSA. Interestingly, patients in
all four reports had received previous vancomycin treat-
ment. A positive correlation between reduced daptomycin
susceptibility and vancomycin resistance in VISA has been
reported. Similar to the mechanism of vancomycin resis-
tance, the physical barrier of a thickened cell wall may con-
tribute to S. aureus resistance to daptomycin [83].
However, a deWnitive mechanism of resistance to daptomy-
cin has not yet been identiWed, and there are no known
transferable elements conferring resistance to the drug. The
isolation of glycopeptide-intermediate S. aureus (GISA) is
rare (i.e., ·0.3%) [84], and cross-resistance of daptomycin
with vancomycin is seen in only a fraction of GISA iso-
lates. Of 15 GISA isolates, 86.7% were susceptible to dap-
tomycin, as reported in the US SENTRY Antimicrobial
Surveillance Program [85]. Among almost 10,000 isolates
tested, only four (0.04%) had a daptomycin MIC of 2 g/
mL (all were glycopeptide-susceptible S. aureus); only two
(0.02%) GISA isolates were found (vancomycin MIC 4 g/
mL; daptomycin MIC 0.5–1.0 g/mL) [86, 87].
To date, daptomycin has been largely used as salvage
therapy following vancomycin failure [88, 89]. In the study
by Fowler et al. [8], most patients had received vancomycin
therapy for a mean of 2 days before starting either dapto-
mycin or standard therapy. A post hoc analysis of MRSA-
infected patients from this study reported that previous
vancomycin therapy did not aVect the clinical outcome of
daptomycin-treated patients [90,  91]. Nonetheless, the
activity of daptomycin against MRSA may be best
exploited in patients who are treated with daptomycin
early; heavy exposure to vancomycin prior to treatment
with daptomycin may increase the likelihood of a suboptimal
response [92].
Summary
Gram-positive organisms, particularly S. aureus, are
responsible for the majority of bone and joint infections.
The prevalence of increasingly resistant organisms is a
major concern, both for achieving therapeutic success and1502 Arch Orthop Trauma Surg (2009) 129:1495–1504
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because of broader cross-resistance implications [27].
While vancomycin has long been the gold standard for the
treatment of bone and joint infections, the emergence of
glycopeptide tolerance and resistance to vancomycin,
resulting in clinical failures [23, 26, 30, 31], demonstrate
the need for alternative treatments.
Daptomycin has exhibited activity in the treatment of
Gram-positive bone and joint infections, including those
caused by MRSA and VRE [93]. It is rapidly bactericidal,
with reported MIC90 concentrations against MRSA and
coagulase-negative staphylococci at 0.5 g/mL [94]. Dap-
tomycin appears eVective against multidrug-resistant
Gram-positive pathogens commonly found in osteomyelitis
and joint infections, even when other Wrst-line antibacterial
treatments have failed [41]. Daptomycin is well tolerated,
with a low potential for adverse events, and the risk of
spontaneous resistance appears low [49,  83]. The novel
mode of action, rapid in vitro bactericidal activity against
growing and stationary-phase bacteria, a once-daily dosing
regimen, and no requirement for drug monitoring contrib-
ute to its potential therapeutic utility [50].
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